Compare YieldMax COIN Option Income Strategy ETF (CONY) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs DexCom, Inc. — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.75 (market cap $370.88M), while DexCom, Inc. trades at $84.38 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 85.9× YieldMax COIN Option Income Strategy ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and DexCom, Inc. for 62 Days on average.
| CONY | DXCM | |
|---|---|---|
Market Cap | $370.88M | $31.86B |
Volume | 595,904 | 3,607,070 |
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $92.34 |
52-Week Low | $17.73 | $54.84 |
Typical Hold Time | 41 Days | 62 Days |
Enterprise Value | — | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.16, down 3.38% today, with a bearish technical outlook as moving averages signal selling pressure. The ETF maintains weekly dividend distributions but faces structural NAV erosion concerns. Recent news highlights regulatory uncertainty impacting crypto-related stocks after Senate cryptocurrency legislation failed to advance.
The outlook remains challenging with significant YTD price decline and ongoing NAV decay despite high distribution rates. Investment opportunity exists for income-focused investors seeking weekly dividends, but structural risks and crypto market volatility present substantial downside exposure.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
